Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms SASAM
Most Recent Events
- 24 Jun 2024 New trial record
- 22 May 2024 Results assessing whether mepolizumab has a significant beneficial effect on Small Airways Diseases (SAD) in severe asthmatics, presented at the 120th International Conference of the American Thoracic Society